“Game-changing” osteoarthritis drug receives £675k funding from Innovate UK
February 19, 2019Manufacturing and Production, Research and Development AKL Research and Development, Innovate UK, osteoarthritis, pharma
A novel and potentially “game-changing” oral therapy for the treatment of osteoarthritis (OA) has received a £675,000 cash injection from …
China to establish national rare disease network
February 19, 2019Manufacturing and Production China, NHC, healthcare, rare diseases
China is set to establish a national collaborative network of hospitals for rare disease diagnosis and treatment to promote early …
Japanese researchers to trial stem cell therapy in four patients with serious spinal injuries
February 19, 2019Manufacturing and Production Japan, Keio University, Parkinson's, cell therapy, iPS
The Japanese health ministry has approved a study testing the use of induced pluripotent stem (iPS) cells to treat four …
Beating the flu
February 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing flu, influenza, pharma, seqirus
On 14 January, the European Commission issued marketing approval for Flucelvax Tetra, the first cell-based, quadrivalent influenza vaccine. Pharmafocus spoke …
Astellas’ Xtandi “significantly improves” progression-free survival in advanced hormone-sensitive prostate cancer
February 18, 2019Research and Development, Sales and Marketing Astellas, Cancer, Xtandi, pharma, prostate cancer
Japanese pharma firm Astellas has lifted the curtain on new data for its androgen receptor signalling inhibitor Xtandi (enzalutamide), when …
Smoking may limit immune system’s ability to fight cancer, study shows
February 18, 2019Sales and Marketing Cancer, cancer research, immune system, immunology, melanoma, oncology, smoking
Smoking may limit the body’s ability to fight melanoma, according to a study published in the journal Cancer Research. The …
Bavencio+Inlyta combo boosts progression-free survival in advanced kidney cancer
February 18, 2019Research and Development, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma
New interim data for the combination of Pfizer’s Bavencio (avelumab) and Merck KGaA’s Inlyta (axitinib) have been released, showing that …
Researchers activate gene to reverse depression in mice
February 18, 2019Sales and Marketing SIRT1, depression, genetics, mental health
Scientists at the Medical College of Georgia at Augusta University were able to directly activate a gene associated with depression …
MSD’s Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma
February 18, 2019Sales and Marketing Cancer, MSD, Merck Sutent, Pfizer, inlyta, keytruda, oncology, rcc, renal cell carcinoma
Merck & Co’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) significantly extended the lives of those with advanced renal …
Lilly and Boehringer’s Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients
February 15, 2019Medical Communications, Research and Development Boehringer, Eli Lilly, cardiovascular disease, pharma, type 2 diabetes
Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself …
Top Ten most popular articles on Pharmafile.com this week!
February 15, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AMR, Dame Sally Davies, FDA, FMD, antibiotic resistance, esketamine, falsified medicines, top 10
News that the FDA’s advisory panel had recommended Janssen’s intranasal esketamine spray Spravato as a treatment for treatment resistant depression, …
Roche’s Perjeta secures NICE approval in adjuvant HER2+ metastatic breast cancer
February 15, 2019Medical Communications, Sales and Marketing NICE, Perjeta, Roche, pharma
NICE has announced its decision to authorise the use of Roche’s Perjeta (pertuzumab) on the NHS for the treatment of …
AstraZeneca to retire MedImmune brand amid restructuring
February 15, 2019Medical Communications AstraZeneca, Business, MedImmune, R&D, biologics, restructuring
AstraZeneca is retiring the MedImmune brand as part of a restructuring that will see biologics integrated into two new R&D …
Lundbeck and Otsuka’s bipolar treatment fails Phase 3 trials due to unexpected placebo effect
February 15, 2019Medical Communications CNS, Lundbeck, Otsuka, Rexulti, bipolar disorder, mental health
Lundbeck and Otsuka’s treatment for bipolar disorder, Rexulti, failed to achieve its primary endpoint in two separate Phase 3 trials. …
First asthma pill in two decades could treat condition by reducing airway muscle
February 14, 2019Research and Development asthma, pharma
Researchers at the University of Leicester alongside colleagues in Vancouver, Canada, have revealed data that supports the efficacy of an …
Takeda’s Adcetris secures expanded approval in Europe for untreated CD30+ Stage IV Hodgkin lymphoma
February 14, 2019Sales and Marketing Adcetris, Cancer, Europe, Hodgkin lymphoma, Takeda, pharma
Takeda’s Adcetris (brentuximab vedotin) has seen its marketing authorisation expanded by the European Commission to include the treatment of previously …
FDA approves Novartis’ Egaten for parasitic infection fascioliasis
February 14, 2019Sales and Marketing Egaten, FDA, Novartis, fascioliasis, pharma
The FDA has taken the decision to authorise the use of Novartis’ Egaten (triclabendazole) in patients older than six years …
Clinigen becomes sole license holder of cancer drug Proleukin in $210m deal
February 14, 2019Sales and Marketing Clinigen, Novartis, Proleukin, pharma
Novartis has arranged to sell the remainder of its rights to its skin and lung cancer drug Proleukin (aldesleukin, recombinant …
J&J acquires lung cancer-focused robotics firm Auris Health in potential $5.75m deal
February 14, 2019Manufacturing and Production, Research and Development, Sales and Marketing Auris Health, Cancer, J&J, JJ, lung cancer, pharma, robotics
In a bid to bolster its footing in providing surgical treatments, Johnson & Johnson has announced it will acquire robotics …
BMS scores expanded European approval for Sprycel in paediatric leukaemia
February 13, 2019Research and Development, Sales and Marketing BMS, Cancer, Europe, Sprycel, leukaemia, pharma
Bristol-Myers Squibb’s Sprycel (dasatinib) has secured an expanded indication in Europe, the company said, with the European Commission greenlighting the …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
